Caribou Biosciences

The two studies describe methods for identifying off-target mutations associated with cell-type-specific SNPs and detecting potential off-target cleavage sites.

The University of California, University of Vienna, and researcher Emmanuelle Charpentier, as well as their commercial partners, are linked by the agreement.

After CRISPR/Cas9 makes a double-strand break in DNA and the cell repairs it, the same set of mutations crop up again and again based on the genomic sequence.

While reimbursement and regulatory issues may make some cautious, investors are encouraged by the promise of breakthrough outcomes in a variety of applications.

Caribou will license its CRISPR technology to Genus to help it create pigs that are resistant to Porcine Reproductive and Respiratory Syndrome Virus.

The financing round includes new investors Anterra Capital, Heritage Group, Maverick Capital Ventures, and Pontifax AgTech.

The Berkeley, California-based company is aiming to turn CRISPR into a platform technology for clinical and industrial applications.

Fight, Fight, Fight!

The USPTO has become involved in the CRISPR-Cas9 patent dispute.

As the interference proceeding to resolve claims in foundational CRISPR patents draws near, Caribou has given IDT worldwide rights to sell RUO reagents. 

In a survey, about half of Canadian government scientists say they still feel as though they cannot speak freely, ScienceInsider reports.

The Atlantic reports that biohacker Josiah Zayner regrets injecting himself with the CRISPR gene-editing tool on stage.

Clinicians in China are moving ahead with a number of CRISPR trials, NPR reports, as the US embarks on its first.

In Nature this week: genomic approaches applied to study Neolithic and Bronze Age Europeans, and more.